Compositions and methods related to flavivirus envelope protein domain III antigens

• US 7,785,799 B2
• Filed: 08/18/2003
• Issued: 08/31/2010
• Est. Priority Date: 08/16/2002
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Holbrook, Michael, Beasley, David, Barrett, Alan
• Primary Examiner(s): CHEN, STACY BROWN
• Application Number:
  US10/524,939
• Publication Number:
  US 20080268423A1
• Time in Patent Office: 2,570 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: G01N 2333/18 Togaviridae; Flaviviridae
• CPC Class Codes: G01N 2469/20 Detection of antibodies in sample from host which are directed against antigens from microorganisms
• CPC Class Codes: G01N 33/56983 Viruses
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention concerns methods and compositions involving flavivirus envelope protein domain III antigens for the detection of virus and detection of antibodies against the virus. Such methods and compositions may be used to detect TBE serocomplex viruses or West Nile virus infection in a subject, patient, animal or biological fluid. The present invention also concerns kits for implementing such methods. In some embodiments, kits contain a recombinant TBE serocomplex virus or West Nile virus envelope protein domain III antigen.

Claims

1. A method of screening for West Nile Virus in a subject or animal host comprising:

a) contacting a sample from the subject or animal with a composition comprising a flavivirus envelope protein domain III polypeptide under conditions that permit formation of specific immunocomplex between an antibody in the sample and the envelope protein domain III peptide, wherein the envelope protein domain III peptide is a West Nile virus envelope protein domain III peptide and has a length of 103 to 118 amino acids and comprises the amino acid sequence of SEQ ID NO;

11; and

b) detecting whether a specific immunocomplex is formed.

2. The method of claim 1, wherein the envelope protein domain III polypeptide is not a fusion protein.

3. The method of claim 1, further comprising at least a second envelope protein domain III polypeptide.

4. The method of claim 1, wherein the immunocomplex is detected using anti-antibody secondary reagents.

5. The method of claim 1, wherein the envelope protein domain III peptide is obtained from a bacteria, a mammalian or an insect cell comprising an expression vector encoding the envelope protein domain III peptide.

6. A composition comprising an isolated West Nile virus envelope protein domain III peptide, wherein the peptide has a length of 103 to 118 amino acids and comprises the amino acid sequence of SEQ ID NO:

11.

7. The composition of claim 6, wherein the envelope protein domain III polypeptide is operatively linked to a substrate.

8. The composition of claim 7, wherein the substrate is a microtiter plate, a bead or a microarray.

12. The composition of claim 7, further comprising an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO:

4, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

4, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

5, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

6, an envelope domain III peptide comprising at most 99 contiguous amino acid sequence of SEQ ID NO;

7, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

8, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

9, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

10, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

12, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

13, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

14, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

15, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

16, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

17, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

18, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

19, an envelope domain III peptide comprising at most 97 contiguous amino acid sequence of SEQ ID NO;

20, and/or an envelope domain III peptide comprising at most 111 contiguous amino acid sequence of SEQ ID NO;

21.

9. A kit for screening for West Nile virus antibodies, in a suitable container, comprising at least one envelope protein domain III polypeptide, wherein the at least one envelope protein domain III polypeptide is a West Nile virus envelope protein domain III peptide, wherein the peptide has a length of 103 to 118 amino acids and comprises the amino acid sequence of SEQ ID NO:

11.

11. A method of screening for West Nile virus in a subject comprising:

a) contacting a sample from the subject with a composition from the kit of claim 9; and

,

b) detecting whether an immunocomplex is formed between an antibody and the envelope protein domain III polypeptide.

13. The kit of claim 9, further comprising an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO:

4, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

4, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

5, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

6, an envelope domain III peptide comprising at most 99 contiguous amino acid sequence of SEQ ID NO;

7, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

8, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

9, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

10, an envelope domain III peptide comprising at most 103 contiguous amino acid sequence of SEQ ID NO;

12, an envelope domain III peptide comprising at most 100 contiguous amino acid sequence of SEQ ID NO;

13, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

14, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

15, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

16, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

17, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

18, an envelope domain III peptide comprising at most 96 contiguous amino acid sequence of SEQ ID NO;

19, an envelope domain III peptide comprising at most 97 contiguous amino acid sequence of SEQ ID NO;

20, and/or an envelope domain III peptide comprising at most 111 contiguous amino acid sequence of SEQ ID NO;

21.

10. A kit for screening for West Nile virus antibodies in a subject comprising:

a) an assay plate comprising a multiplicity of microtiter wells comprising a composition comprising an envelope protein domain III polypeptide capable of binding a West Nile virus antibody in the sample that can specifically bind to the envelope protein domain III polypeptide wherein at least one domain III polypeptide is a West Nile virus envelope protein domain III peptide, wherein the peptide has a length of 103 to 118 amino acids and comprises the amino acid sequence of SEQ ID NO;

11; and

b) a container comprising a labeled secondary antibody having specific binding affinity for a West Nile virus antibody in the sample that can specifically bind to the envelope protein domain III polypeptide.